Advertisement

Neurocritical Care

, 3:189 | Cite as

Myasthenic crisis

Review

Abstract

Myasthenic crisis is a serious occurrence, affecting up to 27% of patients with myasthenia gravis. In the approach to the patient with myasthenic crisis, (1) the diagnosis of myasthenia gravis is confirmed; (2) respiratory failure is evaluated and treated in the intensive care unit, while potential precipitating factors are identified and managed; (3) immunomodulatory treatment is initiated; and (4) complications are avoided or managed promptly. The mortality rate should be 5% or less, with the elderly being most vulnerable.

Key Words

Myasthenia gravis myasthenic crisis critical illness intensive care unit neuromuscular diseases 

References

  1. 1.
    Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997;25:1228–1235.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 1981;377:670–677.PubMedCrossRefGoogle Scholar
  3. 3.
    Oosterhuis HJ. Observations of the natural history of myasthenia gravis and the effect of thymectomy. Ann NY Acad Sci 1981;377:678–690.PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253–1260.PubMedGoogle Scholar
  5. 5.
    Varelas PN, Chua HC, Natterman J, et al. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate. Crit Care Med 2002;30:2663–2668.PubMedCrossRefGoogle Scholar
  6. 6.
    Bedlack RS, Sanders DB. On the concept of myasthenic crisis. J Clin Neuromuscul Dis 2002;4:40–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Keesey JC. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve 2002;26:1–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720–724.PubMedCrossRefGoogle Scholar
  9. 9.
    Zifko UA, Nicolle MW, Grisold W, Bolton CF. Repetitive phrenic nerve stimulation in myasthenia gravis. Neurology 1999;53:1083–1087.PubMedGoogle Scholar
  10. 10.
    Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Antiacetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357–370.PubMedCrossRefGoogle Scholar
  11. 11.
    Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–2311.PubMedCrossRefGoogle Scholar
  12. 12.
    Bedlack RS, Sanders DB. How to handle myasthenic crisis. Essential steps in patient care. Postgrad Med 2000;107:211–214, 220–222.PubMedGoogle Scholar
  13. 13.
    Bucknall RC, Dixon A St J, Glick EN, Woodland J, Zutshi DW. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br Med J 1975;1:600–602.PubMedGoogle Scholar
  14. 14.
    Lensch E, Faust J, Nix WA, Wandel E. Myasthenia gravis after interferon-α treatment. Muscle Nerve 1996;19:927–928.PubMedGoogle Scholar
  15. 15.
    Pascuzzi RM. Medications and myasthenia gravis. Myasthenia Gravis Foundation of America, Inc. 2004. http://www.myasthenia.org/drugs.Google Scholar
  16. 16.
    Drachman DA, Skom JH. Procainamide-a hazard in myasthenia gravis. Arch Neurol 1965;13:316–320.PubMedGoogle Scholar
  17. 17.
    Herishanu Y, Rosenberg P. β-Blockers and myasthenia gravis. Ann Intern Med 1975;83:834–835.PubMedGoogle Scholar
  18. 18.
    Miller RD, Way WL, Katzung BG. The neuromuscular effects of quinidine. Proc Soc Exp Biol Med 1968;129:215–217.PubMedGoogle Scholar
  19. 19.
    Moore B, Safani M, Keesey J. Possible exacerbation of myasthenia gravis by ciprofloxacin. Lancet 1988;1:882.PubMedCrossRefGoogle Scholar
  20. 20.
    Ribera AB, Nastuk WL. The actions and verapamil at the neuromuscular junction. Comp Biochem Physiol C Toxicol Pharmacol 1989;93:137–141.CrossRefGoogle Scholar
  21. 21.
    Torda T. The nature of gentamicin-induced neuromuscular block. Br J Anaesth 1980;52:325–329.PubMedCrossRefGoogle Scholar
  22. 22.
    Eliashiv S, Wirguin I, Brenner T, Argov Z. Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 1990;40:1623–1625.PubMedGoogle Scholar
  23. 23.
    Argov Z, Brenner T, Abramsky O. Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 1986;43:255–256.PubMedGoogle Scholar
  24. 24.
    Brumlik J, Jacobs RS. Myasthenia gravis associated with diphenylhydantoin therapy for epilepsy. Can J Neurol Sci 1974;1:127–129.PubMedGoogle Scholar
  25. 25.
    Pittinger C, Adamson R. Antibiotic blockade of neuromuscular function. Annu Rev Pharmacol 1972;12:169–184.PubMedCrossRefGoogle Scholar
  26. 26.
    Watanabe A, Watanabe T, Obama T, Mawatari T, Ohsawa H, Ichimiya Y, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004;127:868–876.PubMedCrossRefGoogle Scholar
  27. 27.
    Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurologic patients. Semin Neurol 2003;23:97–104.PubMedCrossRefGoogle Scholar
  28. 28.
    Fitting J-W, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 1999;46:887–893.PubMedCrossRefGoogle Scholar
  29. 29.
    Rieder P, Louis M, Jolliet P, Chevrolet J-C. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med 1995;21:663–668.PubMedCrossRefGoogle Scholar
  30. 30.
    Rabinstein A, Wijdicks EF. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation. Neurology 2002;59:1647–1649.PubMedCrossRefGoogle Scholar
  31. 31.
    Fink ME. Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH, ed. Neurological and neurosurgical intensive care, 3rd ed. Raven, New York, 1993.Google Scholar
  32. 32.
    Mayer SA, Thomas CE. Therapy of myasthenic crisis. Crit Care Med 1998;26:1136–1137.PubMedCrossRefGoogle Scholar
  33. 33.
    Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004;350:2452–2460.PubMedCrossRefGoogle Scholar
  34. 34.
    Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629–632.PubMedGoogle Scholar
  35. 35.
    Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56:702–704.PubMedCrossRefGoogle Scholar
  36. 36.
    Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797–1810.PubMedCrossRefGoogle Scholar
  37. 37.
    Guglin M, Campbellone JV, Heintz K, Parrillo JE. Cardiac disease in myasthenia gravis. J Clin Neuromusc Dis 2003;4:199–203.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  1. 1.Departments of Neurology and Pathology (Neuropathology)University of Pittsburgh School of MedicinePittsburgh

Personalised recommendations